Deciphera Pharmaceuticals LLC (DCPH)vsZoetis Inc (ZTS)
DCPH
Deciphera Pharmaceuticals LLC
$25.59
0.00%
HEALTHCARE · Cap: $2.21B
ZTS
Zoetis Inc
$116.71
+0.67%
HEALTHCARE · Cap: $51.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 5312% more annual revenue ($9.47B vs $174.91M). ZTS leads profitability with a 28.2% profit margin vs -108.9%. ZTS earns a higher WallStSmart Score of 64/100 (C+).
DCPH
Avoid30
out of 100
Grade: F
ZTS
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DCPH.
Margin of Safety
-29.1%
Fair Value
$99.69
Current Price
$116.71
$17.02 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 34.5% year-over-year
Every $100 of equity generates 66 in profit
Strong operational efficiency at 34.7%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Areas to Watch
0.0% earnings growth
ROE of -50.4% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Expensive relative to growth rate
Trading at 14.9x book value
3.0% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : DCPH
The strongest argument for DCPH centers on Revenue Growth. Revenue growth of 34.5% demonstrates continued momentum.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.2% and operating margin at 34.7%.
Bear Case : DCPH
The primary concerns for DCPH are EPS Growth, Return on Equity, Free Cash Flow.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.85 is elevated, increasing financial risk.
Key Dynamics to Monitor
DCPH profiles as a hypergrowth stock while ZTS is a value play — different risk/reward profiles.
ZTS carries more volatility with a beta of 0.95 — expect wider price swings.
DCPH is growing revenue faster at 34.5% — sustainability is the question.
ZTS generates stronger free cash flow (732M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (64/100 vs 30/100), backed by strong 28.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Deciphera Pharmaceuticals LLC
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to improve the lives of cancer patients by addressing key drug resistance mechanisms that limit the rate and durability of response to existing cancer therapies. The company is headquartered in Waltham, Massachusetts.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?